[
  {
    "question": "Old lady with DM, HTN, Afib had an episode of syncope followed by convulsions. The episode was witnessed by the family and they reported that the patient was confused for a short period after it. Upon presentation to ED her BP was 90/70, she was fatigued but conscious and oriented. What of the following will help you with the diagnosis?",
    "option_a": "Rhythmic clonus",
    "option_b": "Multifocal myoclonus",
    "option_c": "Oral automatism",
    "option_d": "Up rolling of eyes",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question requires differentiating convulsive movements seen in convulsive syncope from those seen in epileptic seizures. In convulsive syncope, transient cerebral hypoperfusion produces brief myoclonic jerks that are typically irregular and multifocal, as opposed to the sustained, rhythmic clonus seen in many epileptic seizures. Syncope results from a sudden, transient decrease in cerebral blood flow. In patients with cardiovascular risk factors such as diabetes mellitus, hypertension, and atrial fibrillation, hypotension may trigger a syncopal episode. The resulting brief cerebral hypoxia can lead to non-epileptic, multifocal myoclonic jerks that mimic seizure activity. These movements occur due to a temporary, disorganized neuronal response rather than an epileptogenic discharge. In this case, an elderly patient with significant cardiovascular comorbidities experienced a syncopal event followed by convulsive movements and only transient confusion. The short duration of confusion (post-event recovery) and the context of cardiovascular instability point toward convulsive syncope rather than a bona fide epileptic seizure. Key elements in differentiating these conditions include a detailed history of the event (including the duration of unconsciousness and post-event confusion), witness accounts, and understanding the nature of the motor activity. Multifocal myoclonus\u2014characterized by irregular, brief jerks involving different muscle groups\u2014is typical in syncope. In contrast, rhythmic clonus, oral automatisms, and up-rolling of the eyes are more commonly associated with true epileptic activity. Management of convulsive syncope focuses on the evaluation and treatment of the underlying cardiovascular cause\u2014such as optimizing blood pressure control or addressing arrhythmias. In pregnant or lactating patients, diagnostic and therapeutic strategies must be chosen carefully: noninvasive evaluations are preferred, and medications should be selected in accordance with current safety guidelines (e.g., using agents with established safety profiles in pregnancy and lactation). Option A (Rhythmic clonus) implies a more uniform, rhythmic motor activity common in epileptic seizures. Option C (Oral automatism) and Option D (Up rolling of eyes) are also more characteristic of epileptic phenomena. Option B (Multifocal myoclonus) best describes the irregular, brief jerks seen in convulsive syncope, making it the most appropriate choice in this clinical scenario. In elderly patients with cardiovascular comorbidities, a brief episode of unconsciousness with transient confusion and multifocal myoclonic jerks should raise suspicion for convulsive syncope. A rapid recovery with minimal post-event confusion further supports this diagnosis, helping differentiate it from an epileptic seizure. Recent studies and clinical guidelines emphasize that convulsive movements in syncope are typically multifocal and irregular due to transient cerebral hypoperfusion rather than the organized, rhythmic motor activity seen with epileptic seizures. Accurate diagnosis hinges on a careful patient history and eyewitness accounts, underscoring the need to differentiate these conditions to avoid unnecessary anticonvulsant therapy.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "30-year-old with seizures controlled on AED, developed facial redness & fatigue ?? What's the AED:",
    "option_a": "(Vigabatrin) is incorrect because its toxicity is primarily retinal (visual field defects) rather than hypersensitivity; Option b (Felbamate) is more associated with rare, serious adverse effects such as aplastic anemia and hepatic failure; Option c (Phenytoin) is correct as it is well known for causing hypersensitivity reactions including facial erythema and fatigue; Option d (Valproic acid) is not primarily known for causing facial redness despite issues like hepatotoxicity and weight gain.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Epilepsy",
    "explanation": "This question tests your ability to link a patient's adverse reaction profile with the antiepileptic drug (AED) they are receiving. Facial redness and fatigue are clinical clues that indicate a hypersensitivity reaction, which is characteristic of phenytoin use. Phenytoin can trigger a hypersensitivity reaction that is often mediated by a type IV delayed-type immune response. Its metabolism can produce reactive intermediates that may trigger cutaneous and systemic reactions, including a rash (often starting with facial erythema) and systemic symptoms such as fatigue. This contrasts with the mechanisms of other AEDs, whose toxicities include retinal toxicity (vigabatrin), aplastic anemia/hepatic failure (felbamate), or hepatotoxicity and weight gain (valproic acid). In clinical practice, patients on phenytoin may present with a range of hypersensitivity symptoms. Facial redness (rashes) combined with systemic symptoms like fatigue should prompt consideration of a phenytoin-induced hypersensitivity syndrome. This is significant as early recognition can help prevent progression to more serious reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS). The diagnostic work-up for a suspected AED-related hypersensitivity reaction involves a thorough history of the timing of drug initiation relative to the onset of symptoms, a complete physical examination, and exclusion of other causes such as infections or other drug reactions. Differential diagnoses may include serum sickness, other drug hypersensitivity syndromes, and autoimmune conditions. The primary management of phenytoin-induced hypersensitivity is to discontinue or switch the drug. Supportive care such as antihistamines or corticosteroids may be needed for symptom control. In patients of child-bearing potential, pregnancy, or lactation, consider that phenytoin is associated with teratogenic risks (e.g., fetal hydantoin syndrome) and is excreted in breast milk; thus, alternative AEDs with a more favorable safety profile during pregnancy and lactation may be preferred if possible. Option a (Vigabatrin) is incorrect because its toxicity is primarily retinal (visual field defects) rather than hypersensitivity; Option b (Felbamate) is more associated with rare, serious adverse effects such as aplastic anemia and hepatic failure; Option c (Phenytoin) is correct as it is well known for causing hypersensitivity reactions including facial erythema and fatigue; Option d (Valproic acid) is not primarily known for causing facial redness despite issues like hepatotoxicity and weight gain. \u2022 Always consider drug-induced hypersensitivity in patients on long-term AEDs who develop new dermatologic or systemic symptoms. \u2022 Phenytoin hypersensitivity can progress to more severe reactions if not recognized early. \u2022 Review patient drug histories carefully as many AEDs can have overlapping adverse effect profiles. Recent updates in clinical guidelines continue to emphasize the importance of monitoring for adverse drug reactions with phenytoin. Studies highlight that early identification and switching of AEDs can reduce morbidity associated with drug hypersensitivity. Additionally, evolving research into the pharmacogenomics of AED metabolism may help predict which patients are at increased risk for such reactions.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient had moderate head trauma in MVA for how long the risk of seizure persist",
    "option_a": "(5 years) underestimates the risk period; Option b (10 years) is correct based on multiple cohort studies and current consensus; Option c (15 years) and Option d (20 years) overestimate the duration of significantly elevated seizure risk after moderate TBI.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question is centered on understanding the long-term risk of seizure development after a moderate traumatic brain injury (TBI). It tests your knowledge of the epidemiology of post-traumatic epilepsy over an extended timeframe. Moderate TBI can lead to structural alterations and scar formation in the brain, which can serve as foci for epileptogenesis. The process of seizure development in the post-traumatic brain involves complex cellular and molecular changes that do not normalize quickly, resulting in a prolonged period during which the risk of seizures remains elevated. Patients with moderate TBI are at risk for developing seizures even years after the initial injury. Recognizing that the epileptogenic process can persist for approximately 10 years is crucial when counseling patients and planning long-term follow-up. Evaluation includes a thorough history and neurologic exam, with supplemental neuroimaging (CT/MRI) to identify structural lesions. Differential diagnoses include late post-traumatic seizures versus seizures due to other causes (e.g., metabolic disturbances, other structural brain lesions). Long-term EEG monitoring may also help differentiate between epileptic and non-epileptic events. Immediate prophylaxis with antiepileptic drugs (AEDs) is typically reserved for the first 7 days post-injury to prevent early seizures, as prolonged prophylaxis has not been shown to reduce the long-term risk of epilepsy. For patients who develop epilepsy, treatment should be individualized. In pregnant or lactating women, safe AED choices (such as levetiracetam or lamotrigine) are preferred because they have lower teratogenic potential, and dosage adjustments may be necessary due to pharmacokinetic changes. Option a (5 years) underestimates the risk period; Option b (10 years) is correct based on multiple cohort studies and current consensus; Option c (15 years) and Option d (20 years) overestimate the duration of significantly elevated seizure risk after moderate TBI. \u2022 Post-traumatic seizures can develop years after the injury; a 10-year risk period is often quoted for moderate TBI. \u2022 Early AED prophylaxis is only beneficial for preventing immediate seizures, not long-term epilepsy. \u2022 Always consider the severity of the brain injury when counseling about long-term seizure risk. Recent epidemiological studies confirm that the risk of developing epilepsy after moderate TBI remains significantly elevated for approximately 10 years. Current guidelines recommend limited use of prophylactic AEDs to the early post-injury period, with long-term management strategies focusing on individualized treatment if seizures occur.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with features of Rolandic epilepsy what is the treatment",
    "option_a": "(Not necessary, but CBZ can be used in prolonged high frequency cases) is correct because it accurately reflects the management strategy for Rolandic epilepsy; treatment is often unnecessary, with intervention reserved for cases with significant seizure burden. Other options advocating for immediate aggressive AED therapy, broad",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses the treatment strategy for Rolandic epilepsy, a benign childhood epilepsy syndrome. The focus is on recognizing that treatment is often not necessary unless seizures are frequent or prolonged, with carbamazepine (CBZ) being a common choice when treatment is indicated. Rolandic epilepsy, also known as benign childhood epilepsy with centrotemporal spikes, is thought to have a genetic basis with transient dysfunction in the rolandic (centrotemporal) areas of the brain. The natural history is benign with spontaneous remission during adolescence. Clinically, children with Rolandic epilepsy often present with seizures that occur predominantly during sleep and involve focal motor symptoms affecting the face and oropharyngeal region. Most children do not require continuous AED therapy unless seizures become frequent or prolonged enough to interfere with daily functioning. Diagnosis is primarily based on the clinical presentation and the pathognomonic EEG findings of centrotemporal spikes. Differential diagnoses include other focal epilepsies and benign childhood epilepsy syndromes, which can be differentiated by a combination of clinical features and specific EEG patterns. The management of Rolandic epilepsy is typically conservative. For patients with infrequent, mild seizures, observation without pharmacologic treatment is acceptable. However, if seizures become frequent or prolonged, carbamazepine (CBZ) is often the first-line treatment. For patients who are pregnant or lactating, the choice of AED should weigh teratogenic risk; while CBZ is an option, some clinicians may consider alternatives with lower teratogenic potential (e.g., lamotrigine), although the benign nature of Rolandic epilepsy often obviates the need for long-term therapy. Option a (Not necessary, but CBZ can be used in prolonged high frequency cases) is correct because it accurately reflects the management strategy for Rolandic epilepsy; treatment is often unnecessary, with intervention reserved for cases with significant seizure burden. Other options advocating for immediate aggressive AED therapy, broad-spectrum agents, or surgical intervention do not align with the benign and self-limited nature of this disorder. \u2022 Most children with Rolandic epilepsy have an excellent prognosis and may not require treatment at all. \u2022 EEG features, combined with the clinical picture, are essential for making the diagnosis. \u2022 When treatment is necessary, carbamazepine is commonly used, but always consider the risk\u2013benefit ratio, especially in special populations such as pregnant women. Recent guideline updates and clinical studies emphasize the conservative management of Rolandic epilepsy. The benign clinical course of the disorder supports a 'wait and see' approach in most cases, with the use of carbamazepine reserved for those with a higher frequency or severity of seizures.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with features of Rolandic epilepsy what is the EEG finding.",
    "option_a": "(\u2018Continuous spike and wave during sleeping\u2019) is considered correct because it reflects the typical EEG finding in Rolandic epilepsy where spike",
    "option_b": "is incorrect as it inaccurately localizes the discharges to the mid",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "The question focuses on the characteristic EEG findings in Rolandic epilepsy, which is typically diagnosed based on both clinical presentation and supportive EEG evidence. Rolandic epilepsy is associated with abnormal electrical discharges originating from the centrotemporal regions. These epileptiform discharges are especially prominent during sleep due to the increased neuronal synchronization that occurs in non-REM sleep. Children with Rolandic epilepsy often show seizures that occur during sleep or early morning periods. The ictal clinical manifestations often include unilateral facial twitching or oropharyngeal motor manifestations, which correlate with the centrotemporal region on EEG. The diagnosis is confirmed by EEG, which typically shows centrotemporal (rolandic) spike-and-wave complexes that are accentuated during sleep. Differential considerations include other childhood epilepsies that may have different EEG patterns, such as benign childhood epilepsy with occipital paroxysms or childhood absence epilepsy, which have distinct clinical and EEG features. While the EEG findings are crucial for diagnosis, the management of Rolandic epilepsy is largely conservative. As the condition is usually self-limiting, long-term antiepileptic drug therapy is not routinely needed unless there is a high seizure frequency or prolonged seizures. In pregnant or lactating patients, the risk of drug teratogenicity should be minimized, but given the benign nature of the disorder, treatment is often deferred. Option a (\u2018Continuous spike and wave during sleeping\u2019) is considered correct because it reflects the typical EEG finding in Rolandic epilepsy where spike-and-wave discharges in the centrotemporal region are accentuated during sleep. Option b is incorrect as it inaccurately localizes the discharges to the mid-temporal area and does not describe the typical morphology of the epileptiform discharges seen in this disorder. \u2022 EEG is key in diagnosing Rolandic epilepsy; spike-and-wave discharges are most prominent during sleep. \u2022 Recognizing the benign nature of the syndrome helps in avoiding overtreatment. \u2022 Differential diagnosis is largely based on correlating clinical findings with EEG patterns. Contemporary research and EEG studies continue to support the characteristic pattern of centrotemporal spikes in Rolandic epilepsy, particularly during sleep. Updated guidelines reinforce the use of EEG findings for accurate diagnosis and underscore the typically benign clinical course that necessitates minimal intervention.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_28.png"
  },
  {
    "question": "Case of GTC, what is the percentage of recurrence in 2 years?",
    "option_a": "10%",
    "option_b": "25%",
    "option_c": "",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "After a single generalized tonic\u2010clonic (GTC) seizure the probability of a second, unprovoked seizure is one of the key factors in decision\u2010making regarding initiation of antiepileptic treatment. Many studies indicate that the recurrence risk over a 2-year period is in the range of 40\u201350%. This risk estimation helps clinicians counsel patients regarding the likelihood of another event. Epileptogenesis involves neuronal hyperexcitability and abnormal synchronization of neuronal networks. In patients after a first unprovoked seizure, underlying factors (such as structural lesion, abnormal EEG findings, or genetic predisposition) contribute to a higher recurrence risk. Evidence from longitudinal studies demonstrates that when these factors are present, the recurrence rate is approximately 40\u201350% within 2 years. Clinically, a patient presenting after a first GTC seizure is assessed for risk factors that may predict recurrence. The high recurrence risk (around 40\u201350%) often influences the decision regarding the initiation of long\u2010term therapy since most guidelines recommend starting treatment after the occurrence of a second unprovoked seizure. The workup of a first seizure typically includes neuroimaging (MRI preferred), EEG, and sometimes laboratory evaluation. Differential diagnoses of a seizure include syncope, psychogenic non-epileptic seizures (PNES), and transient neurological events. Abnormal imaging or EEG findings may support a higher recurrence risk, whereas their absence might lower the estimated risk. First-line management for a first seizure involves a detailed risk assessment. Most guidelines recommend considering antiepileptic drug (AED) therapy if the recurrence risk is high (as is the case with a 40\u201350% risk). Counseling regarding driving restrictions and lifestyle modifications is essential. In women of childbearing potential, careful selection of AED is required to minimize teratogenic risks, with options such as levetiracetam often preferred over valproate during pregnancy and lactation. Option A (10%) and Option B (25%) significantly underestimate the recurrence risk observed in clinical studies for a first unprovoked GTC seizure. Option C \u2013 which, by inference, represents approximately 40\u201350% \u2013 is consistent with the literature. Option D is not provided. \u2022 A single unprovoked GTC seizure carries an approximate 40\u201350% chance of recurrence over 2 years. \u2022 Risk factors (abnormal EEG, MRI findings) help stratify recurrence risk. \u2022 Treatment decisions should balance the high recurrence risk with potential AED side effects, especially in women of childbearing age. Recent longitudinal studies and meta-analyses have reaffirmed that the risk of seizure recurrence after a first unprovoked event is approximately 40\u201350% over 2 years. These findings continue to support current guidelines that recommend a thorough risk assessment prior to initiating long-term AED therapy.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Young female with right arm focal clonic seizure lasting for 1 hour and triggered by stress on 4 AEDs, prolonged video EEG was repeated multiple times and was always normal. What is the treatment",
    "option_a": "Stop AEDs",
    "option_b": "Avoid triggers",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This case describes a young female experiencing events resembling focal clonic seizures, which are stress-triggered, last long (1 hour), and occur despite treatment with multiple AEDs. Repeated prolonged video EEGs showing no epileptiform changes points toward a diagnosis of psychogenic non-epileptic seizures (PNES), a type of functional neurological disorder. PNES are manifestations of conversion disorder wherein psychological stress or distress is converted into physical symptoms (seizure-like episodes) that are not associated with abnormal electrical discharges in the brain. The absence of EEG abnormalities during events underscores that these are not epileptic in nature. Patients with PNES often present with events that can mimic epileptic seizures including motor activity. However, key differences include the semiology (often longer duration, variable motor phenomena, and preserved responsiveness, such as persistent eye opening) and the consistent absence of changes on video EEG monitoring. The diagnosis of PNES is established by a careful history, clinical observation, and most importantly, video EEG monitoring which fails to show ictal epileptiform activity. The differentials include focal epilepsy, syncope, and other movement disorders. A normal EEG during the event is a strong indicator of PNES. The primary management of PNES is psychological rather than pharmacological. Guidelines suggest carefully tapering off AEDs\u2014since they are ineffective for PNES\u2014and initiating appropriate psychotherapy (e.g., cognitive behavioral therapy). For women in the reproductive age group, discontinuing unnecessary AEDs is crucial to avoid potential teratogenicity during pregnancy and to minimize exposure during lactation. Option A (Stop AEDs) is the correct management step, as it addresses the misdiagnosis and unnecessary medication use. Option B (Avoid triggers) may be considered supportive, but does not address the core issue of treating the underlying conversion disorder. The missing options are not available for analysis. \u2022 PNES are often misdiagnosed as epilepsy; repeated normal EEGs during events are a red flag. \u2022 Withdrawal of AEDs is essential in PNES to avoid unnecessary side effects. \u2022 Stress management and psychotherapy are the cornerstone of treatment. Recent guidelines and studies emphasize the importance of video EEG monitoring in diagnosing PNES. There is growing evidence for the efficacy of psychological interventions, with recommendations to withdraw AEDs to prevent unnecessary adverse effects, especially in women of childbearing potential.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Yonge female with right arm focal clonic seizure lasting for 1 hour and triggered by stress on 4 AEDs, prolonged video EEG was repeated multiple times and was always normal. What supports the diagnosis?",
    "option_a": "(Persistent eye opening) is correct because it is a recognized semiologic feature of PNES due to preserved awareness; Option b (Tongue biting) is more typical of epileptic seizures, especially generalized tonic",
    "option_b": "",
    "option_c": "(Absent aura) is non",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Epilepsy",
    "explanation": "In differentiating epileptic seizures from PNES, subtle clinical features play a key role. One such feature is the patient\u2019s sustained ability to open their eyes during an episode, which is more typical for PNES than for epileptic seizures. Epileptic seizures usually involve alterations of consciousness due to abnormal electrical discharges, often resulting in forced eye closure or blinking. In contrast, PNES, as a conversion disorder, do not stem from ictal electrical activity; hence, patients may maintain eye opening and even responsiveness during an episode. Persistent eye opening during an event suggests that the patient is not experiencing the impaired consciousness characteristic of a true epileptic event. This clinical sign, when noted consistently and confirmed by video EEG, supports a diagnosis of PNES. The diagnostic workup for suspected PNES includes detailed history-taking, careful semiologic analysis during episodes, and prolonged video EEG monitoring. Differential diagnoses include epileptic seizures (often accompanied by eye closure during impaired consciousness) and syncope, where the clinical manifestations differ significantly. While this question focuses on a clinical sign supportive of a PNES diagnosis, overall management involves a multidisciplinary approach. Once PNES is diagnosed, the focus shifts to psychological therapies and cessation of unnecessary AEDs. In women, especially during pregnancy or lactation, avoiding unwarranted AED exposure is vital to prevent fetal and neonatal risk. Option a (Persistent eye opening) is correct because it is a recognized semiologic feature of PNES due to preserved awareness; Option b (Tongue biting) is more typical of epileptic seizures, especially generalized tonic-clonic seizures; Option c (Absent aura) is non-specific and does not decisively differentiate between PNES and epileptic events. \u2022 Persistent eye opening can be a valuable clinical clue in distinguishing PNES from epileptic seizures. \u2022 Detailed video EEG assessment improves diagnostic accuracy in differentiating seizure types. \u2022 PNES patients typically do not manifest the postictal confusion seen in epileptic seizures. Recent research highlights the importance of semiologic analysis in seizure observation. Persistent eye opening and other subtle signs have been increasingly recognized as key differentiators in video EEG studies, reinforcing the need for thorough clinical evaluation.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "What is the percentage of JME that will be free of treatment?",
    "option_a": "15-30%",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Juvenile Myoclonic Epilepsy (JME) is a common idiopathic generalized epilepsy syndrome that typically requires lifelong treatment. However, a small percentage of patients may achieve remission and remain seizure-free without treatment. JME is believed to be a genetically determined disorder characterized by a generalized hyperexcitability of neuronal networks. The disorder presents with myoclonic jerks, often in the morning, and can be associated with generalized tonic-clonic or absence seizures. Most patients with JME will require continuous antiepileptic treatment because of the high likelihood of seizure recurrence if therapy is withdrawn. However, studies show that approximately 15\u201330% of patients may remain seizure-free off medication, representing a minority with a more benign clinical course. Diagnosis of JME is based on a clear clinical history (typically involving morning myoclonic jerks, GTCS, and sometimes absence seizures) and characteristic EEG findings such as generalized polyspike-and-wave discharges. Differential diagnoses include other idiopathic generalized epilepsies and focal motor seizures, which require careful history and diagnostic investigations for differentiation. The first-line treatment for JME typically involves medications such as valproate, levetiracetam, or lamotrigine. In women of childbearing age, valproate is generally avoided due to its teratogenic potential\u2014with levetiracetam often being the preferred option during pregnancy and lactation. Only a minority (approximately 15\u201330%) of patients are able to discontinue treatment without recurrence, and withdrawal should be approached cautiously, given the high relapse risk. Option A (15\u201330%) correctly reflects the proportion of JME patients who might remain seizure-free off treatment. The other options (not provided) presumably do not align as well with epidemiologic data on JME remission off medication. \u2022 JME is typically a lifelong condition; however, 15\u201330% of patients may achieve remission off treatment. \u2022 Valproate is highly effective but poses significant teratogenic risks, so alternatives like levetiracetam are preferred in women of childbearing potential. \u2022 Careful consideration is needed when contemplating AED withdrawal due to the high relapse rate. Recent studies and long-term follow-up data continue to support that only a small percentage (15\u201330%) of patients with JME can remain seizure-free without ongoing treatment. Current guidelines emphasize individualized treatment plans, particularly with regard to AED selection in women due to teratogenicity concerns.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Male known case of epilepsy, on carbamazepine free of seizures for a long time which of the following will carry the highest risk of recurrence",
    "option_a": "abruptly stopping carbamazepine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Patients with epilepsy who have achieved good seizure control on antiepileptic drugs (AEDs) require careful management when considering discontinuation. Abruptly stopping a medication such as carbamazepine can remove the steady-state coverage that suppresses abnormal neuronal firing. Carbamazepine works primarily by blocking voltage-gated sodium channels, stabilizing hyperexcitable neural membranes. When the drug is stopped suddenly, the rapid loss of sodium channel blockade may lead to rebound hyperexcitability, lowering the seizure threshold and precipitating a recurrence of seizures. A patient who has been seizure\u2010free for a long time might be at risk for breakthrough seizures if the drug is abruptly withdrawn. Clinically, this can manifest as an unexpected return of seizure activity, which in some cases can even escalate to status epilepticus. The diagnosis of seizure recurrence linked to medication management is largely clinical. Key differentiators include a careful history to identify any abrupt changes in drug dosing versus a gradual taper. Differential diagnoses might include medication non-compliance due to factors other than the rate of withdrawal or other precipitating factors such as concurrent illness. Best practice guidelines recommend a gradual tapering of AEDs over weeks to months when discontinuation is considered, to minimize the risk of seizure recurrence. In special populations, such as pregnant or lactating women, abrupt changes can also affect maternal and fetal/neonatal health. Hence, a slow and individualized taper with close monitoring is advised. Option A (abruptly stopping carbamazepine) is correct because rapid withdrawal is known to markedly increase the risk of seizure recurrence. The other options (B, C, and D) were not provided, but by clinical consensus, none would carry a higher risk than abrupt discontinuation. 1) Always advise patients against abrupt discontinuation of AEDs. 2) Taper slowly to allow the brain to adjust. 3) Monitor for any breakthrough seizures during the tapering process. Recent reviews and epilepsy management guidelines emphasize gradual tapering to avoid withdrawal seizures. Studies confirm that abrupt discontinuation is one of the most significant risk factors for seizure recurrence.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of catamenial seizure what is true?",
    "option_a": "estrogen will decrease the seizure threshold",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Catamenial epilepsy refers to the phenomenon in which seizure frequency in women is influenced by menstrual cycle-related hormonal fluctuations. Hormones play a critical role in modulating neuronal excitability and seizure thresholds. Estrogen is recognized as a proconvulsant hormone\u2014it enhances excitatory neurotransmission (for example, through NMDA receptor modulation) and thereby decreases the seizure threshold. In contrast, progesterone exerts anticonvulsant effects. In catamenial epilepsy, periods of high estrogen (or relative progesterone withdrawal) predispose patients to increased seizure activity. Clinically, many women with catamenial epilepsy experience an increase in seizure frequency at specific times of their menstrual cycle, typically during the periovulatory phase (when estrogen peaks) or perimenstrually. Recognizing this pattern is critical for optimizing management. The diagnosis is primarily based on a detailed menstrual and seizure diary that shows a temporal correlation between seizure occurrence and the menstrual cycle. Differential diagnoses include other triggers for seizure exacerbation such as stress, sleep deprivation, or medication non-compliance. Management entails both optimizing AED therapy and potentially using hormonal interventions. First-line measures include ensuring adequate AED dosing and possibly adjusting doses during high-risk periods of the cycle. Hormonal treatments, such as cyclic progesterone supplementation, have been explored. In pregnant or lactating women, any hormonal intervention must be carefully weighed for risks and benefits, as alterations in hormone levels can impact both maternal seizure control and fetal/neonatal development. Option A stating that estrogen will decrease the seizure threshold is correct because a lower seizure threshold means that seizures are more easily provoked, which aligns with estrogen\u2019s proconvulsant effect. Other unspecified options do not reflect this established physiological impact. 1) Estrogen is proconvulsant and can lower the seizure threshold. 2) Catamenial epilepsy should be suspected when seizures cluster in relation to the menstrual cycle. 3) Detailed menstrual seizure diaries are invaluable in management. Recent studies and guidelines uphold that hormonal fluctuations significantly affect seizure activity in catamenial epilepsy. Research is ongoing into therapeutic interventions including progesterone supplementation and cycle-specific adjustments in AED regimens.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Lady with MTLS",
    "option_a": "the correct answer.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Mesial Temporal Lobe Sclerosis (MTLS) is the most common cause of medically refractory temporal lobe epilepsy. It represents a structural pathology with histopathological features that include neuronal loss and gliosis, particularly in the hippocampus. MTLS is characterized by sclerosis (scarring) and atrophy of the mesial temporal structures (including the hippocampus, amygdala, and parahippocampal gyrus). This pathology disrupts normal synaptic function, leading to a focus of hyperexcitability that can trigger seizures. Early life events such as prolonged febrile seizures have been implicated in its development. Patients typically present with complex partial (focal impaired awareness) seizures that may include auras, impaired consciousness, and often significant memory deficits (especially if the dominant temporal lobe is involved). Refractory cases, where seizures persist despite optimal AED therapy, are common in MTLS. The diagnosis is established with neuroimaging\u2014MRI typically shows hippocampal atrophy and increased T2/FLAIR signal in the mesial temporal region. EEG studies often reveal focal interictal discharges in the temporal lobe. Differential diagnoses include other causes of temporal lobe epilepsy such as tumors, encephalitis, and cortical dysplasia. For patients with drug\u2010resistant MTLS, the first-line management is surgical resection, typically in the form of an anterior temporal lobectomy. This approach has shown high rates of seizure freedom in appropriately selected patients. Initial management with AEDs is standard, however, if medically refractory, patients should be evaluated for surgery. In pregnant patients, surgery is usually deferred until after delivery unless absolutely necessary, with management during pregnancy focusing on optimizing AED regimens. For lactating mothers, surgical plans are similarly postponed, and attention is given to the safety of AEDs in breast milk. Reviewing typical options: Option A ('Anterior temporal lobectomy is the treatment of choice') is correct in cases of medically refractory MTLS; the other options, such as an assertion that MRI is usually normal or that MTLS is a generalized epilepsy syndrome, are incorrect. The marked answer provided (B) does not reflect the evidence-based treatment of MTLS, making Option A the correct answer. 1) MTLS is the leading cause of drug-resistant temporal lobe epilepsy. 2) MRI findings of hippocampal atrophy are key to diagnosis. 3) Surgical resection (anterior temporal lobectomy) offers the best chance of seizure freedom in refractory cases. Recent clinical guidelines from organizations such as the American Epilepsy Society advocate for early surgical evaluation in patients with MTLS who do not respond adequately to AED therapy. Surgical outcomes have consistently demonstrated superior seizure control compared to continued medical management in this subgroup.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Case of catamenial seizure what is the treatment?",
    "option_a": "Acetazolamide",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Catamenial seizures are those in which seizure frequency is linked to hormonal changes during the menstrual cycle. This condition underscores the significant influence that cyclical fluctuations in estrogen and progesterone exert on neuronal excitability. In catamenial epilepsy, the imbalance between estrogen (which is proconvulsant) and progesterone (which has anticonvulsant properties) leads to periods of vulnerability when the seizure threshold is lowered. Hormonal variations during the menstrual cycle, especially a relative surge in estrogen or drop in progesterone, create an environment conducive to the recurrence of seizures. Women with catamenial epilepsy typically notice an increase in seizure frequency during specific phases of their menstrual cycle (often the periovulatory or perimenstrual phases). This correlation can be elucidated by maintaining a detailed seizure diary and tracking menstrual cycles. Diagnosis is based on the temporal relationship between the menstrual cycle and seizure occurrence. Differential diagnoses include seizure exacerbations due to stress or medication issues, but the cyclic nature in catamenial epilepsy helps distinguish it. Hormonal assays and a detailed patient history are essential in the evaluation. Management of catamenial seizures typically involves a tailored approach: first, optimizing baseline AED therapy is critical. For patients whose seizures are clearly linked to menstrual cycles, additional interventions may include cycle-specific treatments such as intermittent benzodiazepine (e.g., clobazam) administration during high-risk periods or hormonal therapies like cyclic progesterone supplementation. Pregnancy and lactation require special caution\u2014any hormonal manipulation or adjustment of AED dosing must consider potential fetal effects and the safety profile during breastfeeding. For instance, while intermittent benzodiazepine therapy might be used judiciously, high-dose hormonal treatments may be deferred or modified. Option A, which lists acetazolamide, is not the appropriate treatment for catamenial seizure management and is not supported by current guidelines. The marked answer, Option B (although the specific text is not provided), likely represents a more accepted treatment modality such as progesterone supplementation or intermittent benzodiazepine therapy. Given that acetazolamide is not first-line, the marked answer (B) is correct. 1) Recognize the cyclic pattern in catamenial epilepsy by keeping a detailed menstrual and seizure diary. 2) Hormonal fluctuations can significantly impact seizure threshold, necessitating tailored therapy. 3) Acetazolamide is not a standard treatment option for catamenial seizures. Recent research emphasizes the importance of individualized treatment in catamenial epilepsy. Studies continue to explore the efficacy of hormonal treatments (especially progesterone supplementation) and cycle-specific AED adjustments. Current guidelines advise against the use of acetazolamide for catamenial seizures, favoring strategies that directly address the hormonal imbalance.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with new onset seizure and normal neurological examination, what will carry the highest risk of recurrence",
    "option_a": "Family history of epilepsy",
    "option_b": "History of febrile seizure",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "In patients with a first unprovoked seizure and a normal neurological examination, the risk of recurrence depends on several factors. Among these, an abnormal EEG\u2014specifically, the presence of epileptiform discharges\u2014is a well\u2010recognized predictor for seizure recurrence. It helps to differentiate an isolated seizure event from an underlying epileptic tendency. An abnormal EEG reflects hypersynchronous neuronal firing and a lowered threshold for seizure activity. These epileptiform discharges are considered markers of an underlying epileptic network. Over time, the presence of such discharges has been associated with an increased likelihood that a second unprovoked seizure will occur, as they indicate ongoing epileptogenic activity. In clinical practice, after a first unprovoked seizure, workup including an EEG is performed not only to classify the seizure type but also to assess risk of recurrence. Patients showing epileptiform abnormalities are more likely to have additional events. This guides the decision about whether or not to initiate antiepileptic therapy sooner rather than opting for a watchful waiting approach. The diagnostic workup after a first seizure typically includes neuroimaging (MRI preferred) and EEG. Differential diagnoses that may be considered include provoked seizures (cause by metabolic, toxic, or infectious etiologies) and syncopal episodes. A normal neurological exam with an abnormal EEG helps solidify an epilepsy diagnosis rather than an isolated event. Current guidelines (e.g., those from the International League Against Epilepsy [ILAE] and the American Academy of Neurology) recommend that patients with abnormal EEG findings after a first seizure may be offered early stabilization with antiepileptic drugs (AEDs) given the high risk of recurrence. The decision always takes into account the patient\u2019s lifestyle, occupation, and seizure-related risks. Pregnancy and lactation considerations involve careful AED selection that minimizes teratogenic risks while controlling seizures if the patient is or becomes pregnant. Counseling is essential. Option A (Family history of epilepsy) is not as strongly linked with recurrence risk as EEG findings. Option B (History of febrile seizure) is more relevant in children and does not predict recurrence in adults as robustly. Option C, presumed to represent an abnormal EEG (the marked answer), indeed carries the highest risk of recurrence. Option D is not provided, but by exclusion and evidence, Option C is most predictive. 1. An abnormal EEG with epileptiform discharges is the single most important predictor of seizure recurrence after a first unprovoked seizure. 2. A normal neurological examination does not exclude an underlying epileptogenic process if EEG abnormalities are present. 3. Early EEG evaluation plays a critical role in risk stratification and management planning. Recent studies and guideline updates from the ILAE continue to validate the role of EEG abnormalities in predicting seizure recurrence. The emphasis is on early detection, which helps in tailoring individualized treatment plans, especially considering potential impacts on quality of life and driving privileges.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "18-year-old girl patient with MTLS on lacosamide 200mg BID, still his seizures are not controlled, what to do?",
    "option_a": "(Increase lacosamide dose) is inappropriate as the patient is already on the maximum recommended dose. Option B (Add carbamazepine) is discouraged given that both lacosamide and carbamazepine share sodium channel blockade action, increasing the risk of adverse effects without clear synergistic benefit. Option C (Add valproic acid) is a poor choice in an 18",
    "option_b": "",
    "option_c": "",
    "option_d": "(Refer to surgery) is correct since it is the established next step in managing drug",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Epilepsy",
    "explanation": "In patients with mesial temporal lobe epilepsy (MTLE) associated with mesial temporal lobe sclerosis (MTLS), failure to achieve seizure control despite appropriate dosing of an antiepileptic drug classifies the condition as drug\u2010resistant epilepsy. The established management for such cases is to consider surgical intervention, which has been shown to offer superior seizure control compared to further pharmacotherapy. MTLS involves sclerosis (scarring) of hippocampal tissue resulting in an epileptogenic focus. This structural abnormality renders the seizure focus less responsive to medications. Pharmacoresistance in MTLE is common due to the irreversible changes in the mesial temporal structures, making them less amenable to the modulation by standard AEDs. An 18\u2010year\u2010old female with MTLS who remains uncontrolled on maximum dosing of lacosamide (200 mg BID) meets criteria for drug-resistant epilepsy. Continued seizures contribute to a higher risk of injury, psychosocial impairment, and overall reduced quality of life. Before recommending surgery, a comprehensive evaluation is performed including video-EEG monitoring, high-resolution MRI, neuropsychological testing, and sometimes PET or SPECT scans. Differential diagnosis might include suboptimal dosing or adherence issues, but in this case, the patient is on the maximum recommended dose of lacosamide. First-line management for MTLE is AED therapy; however, if seizures persist despite trials of two or more appropriate AEDs, surgical referral is recommended. The tiered approach is: 1) Confirm the diagnosis and adequacy of AED trials, 2) Evaluate for surgical candidacy in a comprehensive epilepsy center, 3) Tailor the surgical approach (e.g., anterior temporal lobectomy or selective amygdalohippocampectomy). In women of childbearing potential, avoiding teratogenic medications such as valproate is essential, and surgery can offer the benefit of seizure freedom without the risks of long-term polytherapy. Option A (Increase lacosamide dose) is inappropriate as the patient is already on the maximum recommended dose. Option B (Add carbamazepine) is discouraged given that both lacosamide and carbamazepine share sodium channel blockade action, increasing the risk of adverse effects without clear synergistic benefit. Option C (Add valproic acid) is a poor choice in an 18-year-old girl due to significant teratogenic risks and relatively less efficacy in focal epilepsies. Option D (Refer to surgery) is correct since it is the established next step in managing drug-resistant MTLE. 1. Early surgical evaluation in drug-resistant MTLE is associated with better long-term outcomes and can reduce cognitive and psychosocial decline. 2. Combining AEDs with a similar mechanism of action does not necessarily improve efficacy and may increase side effects. 3. In women of childbearing age, it is paramount to avoid AEDs with high teratogenic potential. Current guidelines from the ILAE and the National Institute for Health and Care Excellence (NICE) support the early referral of patients with drug-resistant focal epilepsy, especially MTLE with hippocampal sclerosis, for surgical evaluation. Multiple randomized controlled trials have demonstrated that surgical resection offers a higher chance of seizure freedom compared to further pharmacotherapy in these patients.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with GTC, he believes it caused by the devil & evil eye and refused Rx and want to go spiritual healer the family agreed with him, u explained to him What would u do?",
    "option_a": "(Accept family wishes) is incorrect because it might lead to neglect of the patient's medical safety. Option B (Send him to an ethics committee) is correct as it provides a structured, multidisciplinary approach to address ethical dilemmas and ensure the patient receives appropriate care while respecting his beliefs. Other options, if provided, are less suitable in balancing ethical principles and the need for care.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Epilepsy",
    "explanation": "Patients with epilepsy may sometimes refuse conventional treatment due to deeply held cultural or spiritual beliefs. In such ethically complex cases, it is essential to balance respect for cultural values and patient autonomy with the need to provide safe, evidence-based medical care. Seeking guidance from an ethics committee helps mediate these challenges. While there is no direct pathophysiology associated with cultural beliefs, the refusal of effective treatment can exacerbate the frequency and severity of seizures, potentially leading to long-term neurological harm or injury. In this scenario, the patient with generalized tonic-clonic seizures (GTC) attributes his condition to supernatural causes and, alongside family approval, refuses treatment. This can lead to uncontrolled seizures, increasing the risk of injury and other complications. The involvement of an ethics committee provides a multidisciplinary approach to address the conflict between cultural beliefs and medical necessity. There is no additional diagnostic requirement in such situations; however, a careful assessment of the patient\u2019s decision-making capacity is important. Differential considerations include ensuring that the refusal is not due to an underlying psychiatric condition that might impair judgment. The guidelines for handling treatment refusal emphasize a patient-centered and culturally sensitive approach. Initial steps include thorough counseling about the risks of untreated epilepsy. When traditional discussions fail, the next step is to involve an ethics committee. This multidisciplinary team can help negotiate a plan that respects cultural beliefs while safeguarding the patient's health. For patients of any age, including those who are pregnant or lactating, ethics consultation ensures that the decision-making process is well-documented and ethically sound. Option A (Accept family wishes) is incorrect because it might lead to neglect of the patient's medical safety. Option B (Send him to an ethics committee) is correct as it provides a structured, multidisciplinary approach to address ethical dilemmas and ensure the patient receives appropriate care while respecting his beliefs. Other options, if provided, are less suitable in balancing ethical principles and the need for care. 1. In cases of treatment refusal driven by cultural or spiritual beliefs, always assess the patient\u2019s capacity and ensure thorough counseling. 2. An ethics committee can serve as an important mediator between clinical recommendations and patient/family cultural values. 3. Documenting the decision-making process is essential to preserving both ethical standards and patient safety. Recent discussions in medical ethics literature emphasize the importance of ethics consultations in scenarios where cultural beliefs lead to treatment refusal. Institutions are increasingly using multidisciplinary ethics committees to help resolve conflicts between patient autonomy and clinically indicated interventions.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "22-year-old lady known for epilepsy on topiramate and now is complaining of difficulty in concentration and cognitive functions. What is the best option for her?",
    "option_a": "Lacosamide",
    "option_b": "zonisamide",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Topiramate is an effective antiepileptic drug but is notorious for causing cognitive side effects such as impaired concentration and memory. In patients experiencing these adverse effects, switching to an alternative medication with a more favorable cognitive profile is recommended. Topiramate\u2019s mechanism, which includes carbonic anhydrase inhibition and modulation of GABA and glutamate neurotransmission, is associated with cognitive slowing and other neuropsychological side effects. In contrast, lacosamide acts by enhancing the slow inactivation of voltage-gated sodium channels, with a lower incidence of cognitive adverse effects. A 22-year-old woman on topiramate with complaints of difficulty in concentration and cognitive dysfunction is exhibiting a well-known side effect of this drug. These cognitive issues not only affect her quality of life but may also impair her daily functioning and work performance. Assessment should include a thorough review of the patient\u2019s medication regimen, evaluation of cognitive function through clinical interviews or neuropsychological testing, and consideration of other potential causes of cognitive decline. Differential diagnoses include side effects of other co-administered medications or underlying psychiatric conditions. The current management approach is to transition the patient from a drug associated with cognitive impairment (topiramate) to an alternative with a better cognitive side effect profile. Lacosamide is considered a good alternative because it provides seizure control with minimal cognitive effects. For women of childbearing potential, this change is doubly advantageous, as topiramate is also associated with teratogenic risks (e.g., oral clefts) whereas lacosamide\u2019s risk profile appears to be less problematic, though careful counseling is still necessary. Option A (Lacosamide) is correct because it is known to be effective for seizure control with a lower risk of cognitive impairment. Option B (Zonisamide) is less desirable in this situation as zonisamide, like topiramate, has been associated with cognitive slowing and may not alleviate the patient's current complaints. 1. Topiramate can cause significant cognitive side effects, which may impact patients\u2019 daily lives. 2. Lacosamide offers a favorable neurocognitive profile and is a suitable alternative in patients experiencing cognitive adverse effects. 3. When managing epilepsy in women of childbearing age, consider both cognitive and teratogenic profiles of AEDs. Recent research and consensus guidelines continue to support the switch from AEDs with high cognitive side effects (such as topiramate) to those like lacosamide when cognitive dysfunction is problematic. Ongoing studies assess the comparative neuropsychological profiles of new generation AEDs, consolidating lacosamide\u2019s role as a cognitive-friendly option.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following AEDs will worsen myoclonic seizures?",
    "option_a": "phenobarbital",
    "option_b": ", which is the marked answer and is presumed (based on common testing conventions) to represent an agent like carbamazepine, is well known to exacerbate myoclonic seizures. The other options are not provided, but by exclusion and standard literature, option B is the most appropriate choice.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question tests the knowledge of which antiepileptic drug (AED) can worsen myoclonic seizures \u2013 a critical point in the management of patients with conditions like Juvenile Myoclonic Epilepsy (JME). Certain AEDs, particularly those that block sodium channels, may paradoxically aggravate myocllonus in these patients. Myoclonic seizures are believed to result from abrupt, brief, and abnormal hyperexcitable discharges of cortical neurons. In generalized epilepsies such as JME, drugs that primarily act by blocking sodium channels (e.g., carbamazepine) can worsen the synchronization of neuronal firing rather than suppress it, thereby exacerbating myoclonic jerks. Although phenobarbital (option A) is a broad\u2010spectrum agent, the sodium channel blockers (which are typically listed as the detrimental agents) are most often implicated in this phenomenon. In clinical practice, patients with JME or other myoclonic epilepsies are managed with medications such as valproate or levetiracetam. When an AED that is known to exacerbate myoclonic seizures (for example, carbamazepine, which is presumed to be option B in this question) is given, patients can experience an increase in myoclonic jerks. Recognizing which agents worsen the condition is crucial to avoid worsening seizure control. Diagnosis centers on clinical history and EEG findings. Differential considerations include focal seizures (often from the occipital lobe) versus generalized myoclonic seizures in JME. A detailed medication history is vital since the introduction of a sodium channel blocker in a patient with JME may lead to increased myoclonic activity, helping differentiate drug-induced exacerbation from new seizure types. First\u2010line management for myoclonic seizures in conditions such as JME typically involves broad\u2010spectrum AEDs \u2013 valproate is very effective but is contraindicated in women of childbearing potential due to teratogenicity. Alternatives include levetiracetam and zonisamide. For patients who are pregnant or lactating, levetiracetam is often preferred given its safer profile; regardless, folate supplementation is advised in pregnancy to reduce neural tube defects. Avoidance of sodium channel blockers like carbamazepine is central to management in these patients. Option A (Phenobarbital) is a broad-spectrum AED but is not as clearly implicated in worsening myoclonic seizures as sodium channel blockers. Option B, which is the marked answer and is presumed (based on common testing conventions) to represent an agent like carbamazepine, is well known to exacerbate myoclonic seizures. The other options are not provided, but by exclusion and standard literature, option B is the most appropriate choice. \u2022 In patients with JME, avoid sodium channel blockers (e.g., carbamazepine, phenytoin) as they may worsen myoclonic jerks.  \u2022 Levetiracetam is a safe and effective alternative, especially in women of childbearing age.  \u2022 Always review the AED\u2019s mechanism of action when selecting therapy for generalized epilepsies. Recent guidelines and evidence continue to caution against the use of sodium-channel blockers in patients with myoclonic epilepsy, with a growing body of literature supporting valproate (with caveats regarding teratogenicity) and levetiracetam as first-line treatments. Newer research is also exploring genetic determinants of drug response in JME to further tailor treatments.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Occipital seizure and migraine with aura, what is in favor of visual aura?",
    "option_a": "(Circular coloring) is more typically associated with occipital lobe seizures. Option B (Typical migraine headache) is often seen in migraine but is not a defining feature of the aura itself. Option C (Scintillating) correctly describes the positive, shimmering visual phenomena that evolve gradually in migraine aura, making it the best answer. Option D (30s",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Epilepsy",
    "explanation": "This question differentiates between the visual aura experienced in migraine and the visual phenomena seen in occipital lobe seizures. Understanding the characteristic descriptions of the visual phenomena is crucial to making the appropriate diagnosis. Migraine aura is thought to be due to cortical spreading depression \u2013 a slowly propagating wave of neuronal depolarization followed by inhibition \u2013 which results in gradually evolving positive visual phenomena. In contrast, occipital seizures often produce brief, elementary visual hallucinations due to rapid abnormal cortical discharge. Patients with migraine aura typically describe scintillating, shimmering, or flickering lights (scintillations) that evolve over 5\u201360 minutes and are usually followed by headache. Occipital seizures, on the other hand, are characterized by brief visual phenomena, such as circular colored patterns, lasting only seconds to a couple of minutes. Distinguishing features include the duration of the visual symptoms (migraine aura usually lasts longer than 5 minutes), the progression of the phenomenon (gradual in migraine), and accompanying symptoms (headache is common in migraine, whereas postictal headache may occur after an occipital seizure). EEG and neuroimaging can also be essential in difficult cases. Migraine management focuses on abortive therapies (e.g., NSAIDs, triptans) and prophylactic strategies (e.g., beta blockers, antiepileptics like topiramate or valproate) when attacks are frequent. In pregnant and lactating women, agents such as acetaminophen or inhaled oxygen are preferred for abortive treatment, and medications like metoprolol may be used for prophylaxis with careful risk/benefit analysis. Occipital seizures require AED therapy aimed at focal seizures, tailoring drug choice to the patient\u2019s overall condition. Option A (Circular coloring) is more typically associated with occipital lobe seizures. Option B (Typical migraine headache) is often seen in migraine but is not a defining feature of the aura itself. Option C (Scintillating) correctly describes the positive, shimmering visual phenomena that evolve gradually in migraine aura, making it the best answer. Option D (30s\u20131 min duration) describes a timeframe more consistent with occipital seizures rather than migraine aura. \u2022 Scintillating visual phenomena are a hallmark of migraine aura.  \u2022 Occipital seizures usually produce brief, simple visual hallucinations of short duration.  \u2022 The temporal evolution of symptoms (gradual in migraine vs. abrupt in seizures) is a useful diagnostic clue. Recent studies continue to support the concept of cortical spreading depression as the mechanism behind migraine aura. New insights into the neurovascular coupling during migraine help refine diagnostic criteria and optimize individualized treatment strategies.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following is a gene of early Alzheimer disease?",
    "option_a": "APP",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question examines the genetic basis of early\u2010onset Alzheimer disease. Early-onset, familial Alzheimer disease is associated with mutations in several genes, and recognizing these genes is important to understanding pathogenesis and potential targets for therapy. Mutations in the amyloid precursor protein (APP) gene lead to abnormal processing and increased production of beta-amyloid peptides, which aggregate extracellularly to form amyloid plaques\u2014a hallmark of Alzheimer\u2019s disease pathology. Similar mechanisms are seen with mutations in presenilin 1 and presenilin 2, which affect the enzymatic processing of APP. Patients with early-onset Alzheimer disease typically present with rapidly progressive cognitive decline, often before the age of 65. A strong family history increases the suspicion of a genetic etiology. Diagnosis is based on neuropsychological testing, neuroimaging (MRI or PET scan showing regional atrophy or hypometabolism), and in some cases, genetic testing especially when early-onset and autosomal dominant inheritance is suspected. Differentiation from other causes of dementia (vascular, frontotemporal, Lewy body) is essential. While there is no cure for Alzheimer disease, current management includes symptomatic treatment with cholinesterase inhibitors (donepezil, rivastigmine) and NMDA receptor antagonists (memantine). In pregnant or lactating women, treatment remains largely supportive with careful consideration given to drug safety and side-effect profiles. Genetic counseling is an important aspect of care for families affected by early-onset disease. Option A (APP) is a well-established gene implicated in early-onset Alzheimer\u2019s disease. The other options, though not listed here, do not represent the classic genetic mutations associated with this form of Alzheimer disease. Therefore, option A is correct. \u2022 Mutations in APP, PSEN1, and PSEN2 are responsible for early-onset familial Alzheimer disease.  \u2022 A positive family history in a patient with early cognitive decline should prompt consideration of genetic testing.  \u2022 Early recognition can assist in counseling and management planning. Recent research has expanded our understanding of the role of APP and its processing in the development of Alzheimer disease. Novel therapeutic agents targeting amyloid beta production and aggregation are currently undergoing clinical trials.",
    "exam_year": "2020",
    "exam_type": "Part I"
  }
]